Serum and molecular biological markers in cervical carcinoma and cervical carcinoma in situ

CME Journal of Gynecologic Oncology

Volumn 6, Issue 1, 2001, Pages 81-85

  Geisler, J P ^a   Geisler, H E ^a   Miller, G A ^a   Wiemann, M C ^a   Zhou, Z ^a   Miller, J ^a   Crabtree, W ^a  

^a ST VINCENT HOSPITAL   (United States)

Author keywords

Cervical carcinoma; CIN; Molecular markers

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; KALININ; MATRIX METALLOPROTEINASE; SQUAMOUS CELL CARCINOMA ANTIGEN; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER;

ANTIGEN DETECTION; ANTIGEN EXPRESSION; CONFERENCE PAPER; FEMALE; HUMAN; PROGNOSIS; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU;

EID: 0034907249     PISSN: 12199087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (57)

1. Global cancer statistics
2. Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma
3. Value of tumor antigen (TA-4) of squamous cell carcinoma antigen in predicting the extent of cervical cancer
4. The value of squamous cell carcinoma antigen as a predictor of nodal metastasis in cervical cancer
5. Prognostic significance of serum tumour markers in carcinoma of the cervix
6. Squamous-cell carcinoma antigen (SCC-A) values related to clinical outcome of pre-invasive and invasive cervical carcinoma
7. Application of tuymor markers CEA, TPA, and SCC-Ag in patients with low-risk FIGO stage IB and IIA squamous cell carcinoma of the uterine cervix
8. The clinical value of tissue polypeptide antigen in patients with gynecologic tumors
9. The prognostic significance of pre- and posttreatment SCC levels in patients with squamous cell carcinoma of the cervix treated by radiotherapy
10. Multiple tumour marker assays in advanced cervical cancer: Relationship tp chemotherapy response and clinical outcome
11. Clinical evaluation of serum and immunohistochemical expression of SCC and CA 19-9 in radiation therapy for cervical cancer
12. Tumor-associated antigens CEA, CA125, SCC and TPS in gynaecological cancer
13. Tissue polypeptide specific antigen in the follow-up of ovarian and cervical cancer patients
14. Serum antibodies to the 27-kd heat shock protein in women with gynecologic cancers
15. Quantification of p53 in epithelial ovarian cancer
16. P53 and bcl-2 in epithelial ovarian carcinoma: Their value as prognostic indicators at a median of 60 months of follow-up
17. P53 as a prognostic indicator in endometrial cancer
18. P53 expression as a prognostic indicator of 5-year survival in endometrial cancer
19. Telomerase, p53 and human papillomavirus infection in the uterine cervix
20. The possible role of p53 and bcl-2 expression in cervical carcinomas and their premalignant lesions
21. An immunohistochemical analysis of heat shock protein 70, p53, and estrogen receptor status in carcinoma of the uterine cervix
22. Bcl-2 immunoreactivity but not p53 accumulation associated with tumour response to radiotherapy in cervical carcinoma
23. Immunohistochemical analysis of p53 protein over expression in normal, premalignant, and malignant tissues in the cervix uteri
24. P53 expression in carcinoma of the cervix
25. Expression of p27 and p53 in cervical squamous cell carcinoma patients treated with radiotherapy alone
26. Bax and bcl-2 expressions predict response to radiotherapy in human cervical carcinoma
27. Gynecology: Expression and mutational analysis of p53 in stage IB and IIA cervical cancers
28. Msh2, mlh1, p53, bcl-2, and Bax expression in invasive and in situ squamous cell carcinoma of the uterine cervix
29. Lack of bcl-2 persistence: As an independent prognostic indicator of poor prognosis in endometrial carcinoma
30. Apoptosis and the expression of BAX and bcl-2 in squamous cell carcinoma and adenocarcinoma of the uterine cervix
31. Analysis of bcl-2, Bax and surviving genes in uterine cancer
32. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers
33. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors
34. Loss of Fhit expression in invasive cervical carcinomas and intraepithelial lesions associated with invasive disease
35. Role of TSG101 in uterine cervix cancer
36. High cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion
37. Laminin-5 as a marker of invasiveness in cervical lesions
38. Expression of MN/CA9 protein in papanicolaou smears containing atypical glandular cells of undetermined significance is a diagnostic biomarker of cervical dysplasia and neoplasia
39. Heat shock protein 27: An independent prognostic indicator of survival in patients with epithelial ovarian carcinoma
40. A study of heat shock protein 27 in endometrial carcinoma
41. Prognostic value of CD44 splice variant expression in ovarian cancer
42. Serum assay of soluble CD44 standard (sCD44-st), CD44 splice variant v5 (sCD44-v5), and CD44 splice variant v6 (sCD44-v6) in patients with epithelial ovarian cancer
43. High serum level of soluble CD44 variant isoform v5 are associated with favourable clinical outcome in ovarian cancer
44. Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partially mediated by CD44h
45. In vivo inhibition of cd44 limits intra-abdominal spread of human ovarian cancer xenograft in nude mice: A novel role for CD44 in the process of peritoneal implantation
46. Expression of CD44 in uterine cervical squamous neoplasia: A predictor of microinvasion?
47. CD44 is a marker of endocervical neoplasia
48. CD44 exon v6 correlates with cellular differentiation but not with progression and metastasis of cervical cancer
49. Down-regulation of CD44 standard and variant isoforms during development and progression of uterine cervical tumours
50. Tumor invasion and metastasis: An imbalance of positive and negative regulation
51. Matrix-metalloproteinases and their inhibitors in plasma and tissue of patients with renal cell carcinoma
52. MMP-2 and TIMP-s expression correlates with poor prognosis in cervical - A clinicopathologic study using immunohistochemistry and mRNA in situ hybridization
53. Matrix metalloproteinase 2 immunoreactive protein appears early in cervical epithelaial dedifferentiation
54. In situ detection of PCR-amplified metalloproteinase cDNAs, their inhibitors and human papillomavirus transcripts in cervical carcinoma cell lines
55. Expression of matrix metalloproteinase-9 in squamous cell carcinoma of the uterine cervix - Clinicopathologic study using immunohistochemistry and mRNA in situ hybridization
56. Pelvic exenteration in the elderly female